Medivir is also developing Hepatitis C drug (TMC435) with Tibotec Pharmaceuticals. Medivir announced positive interim Phase IIb data on efficacy of TMC 435.
TMC435 is a once daily protease inhibitor jointly developed by Medivir and Tibotec Pharmaceuticals to treat hepatitis C virus infections. TMC435 is currently being studied in three phase 2b clinical trials, TMC435-C205, TMC435-C206 and TMC435-C215, in G1 treatment-naive and in G1 patients that failed previous IFN-based treatment. TMC435 is planned to enter phase 3 studies early 2011.